ESR1 and breast carcinoma: A recent report from the International Breast Cancer Study Group, in which the hazard rates of breast cancer recurrence were estimated from 4105 breast cancer patients and 24 years of follow-up, also showed that the hazard for experiencing late relapse remains elevated and fairly stable beyond 10 years in ER-positive patients [41].